Ieq Capital LLC Buys New Holdings in ICU Medical, Inc. $ICUI

Key Points

• Ieq Capital initiated a position in ICU Medical during the second quarter, buying 6,178 shares valued at approximately $906,000. Institutional investors collectively own 96.10% of the company, with major holders including BlackRock, Vanguard and Janus Henderson.
• Analyst sentiment remains generally positive, with ICU Medical carrying a consensus “Moderate Buy” rating and an average price target of $192.80. Recent recommendations included price-target increases and upgrades to “strong buy,” though some firms downgraded the stock to “hold” or “market perform.”
• ICU Medical exceeded quarterly expectations, reporting EPS of $2.37 versus the $1.91 consensus estimate and revenue of $547.88 million. The stock opened at $175.10, while insiders have sold 16,974 shares worth about $3.09 million over the past 90 days.

Ieq Capital LLC purchased a new position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,178 shares of the medical instruments supplier's stock, valued at approximately $906,000.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of ICU Medical in the 2nd quarter valued at $550,250,000. Vanguard Group Inc. lifted its position in ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock valued at $387,313,000 after purchasing an additional 89,755 shares during the period. Janus Henderson Group PLC lifted its position in ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier's stock valued at $345,607,000 after purchasing an additional 99,256 shares during the period. Millennium Management LLC boosted its holdings in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after purchasing an additional 690,694 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in ICU Medical by 6.8% in the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock valued at $127,053,000 after purchasing an additional 63,026 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ben Sousa sold 2,250 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider directly owned 3,076 shares in the company, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elisha W. Finney sold 378 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director directly owned 4,871 shares of the company's stock, valued at approximately $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 16,974 shares of company stock worth $3,085,844. Company insiders own 2.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Needham & Company LLC lifted their price objective on ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Jefferies Financial Group raised ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Sanford C. Bernstein cut ICU Medical to a "market perform" rating in a research report on Monday, June 15th. Finally, Zacks Research downgraded ICU Medical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.

ICU Medical Stock Down 2.5%

ICUI opened at $175.10 on Friday. The company has a fifty day moving average of $163.95 and a two-hundred day moving average of $143.89. The stock has a market capitalization of $4.38 billion, a price-to-earnings ratio of 148.39, a PEG ratio of 2.27 and a beta of 0.74. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period in the prior year, the company posted $2.10 EPS. The company's revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts expect that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source